Avenzo Therapeutics
Avenzo Therapeutics is a clinical-stage biotechnology company developing next-generation oncology therapeutics. Their lead drug candidate, AVZO-021, is a CDK2 inhibitor currently in a Phase 1 clinical study for treating advanced solid tumors. The company aims to advance innovative oncology therapies for patients.
Buy Funded Startups lists
Funding Round: Series A1
Funding Amount: $150M
Date: 26-Mar-2024
Investors: New Enterprise Associates (NEA), Deep Track Capital, Sofinnova Investments, Sands Capital, INCE Capital, TF Capital, Delos Capital, Quan Capital
Markets: Biotechnology, Oncology
HQ: San Diego, California, United States
Founded: 2022
Website: http://www.avenzotx.com/
LinkedIn: https://www.linkedin.com/company/avenzotx
Crunchbase: https://www.crunchbase.com/organization/avenzo-therapeutics
Leave a Comment
Comments
No comments yet.